These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 8034509)

  • 1. Successful control of poliomyelitis by a combined OPV/IPV polio vaccine program in the West Bank and Gaza, 1978-93.
    Tulchinsky T; Abed Y; Handsher R; Toubassi N; Acker C; Melnick J
    Isr J Med Sci; 1994; 30(5-6):489-94. PubMed ID: 8034509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poliomyelitis control in Israel, the West Bank and Gaza Strip: changing strategies with the goal of eradication in an endemic area.
    Goldblum N; Gerichter CB; Tulchinsky TH; Melnick JL
    Bull World Health Organ; 1994; 72(5):783-96. PubMed ID: 7955030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Worldwide eradication of poliomyelitis].
    Rasch G; Schreier E; Kiehl W; Kurth R
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
    Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
    J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel.
    Swartz TA; Green MS; Handscher R; Sofer D; Cohen-Dar M; Shohat T; Habib S; Barak E; Dror Z; Somekh E; Peled-Leviathan T; Yulzari R; Libling A; Mendelson E; Shulman LM
    Vaccine; 2008 Feb; 26(8):1083-90. PubMed ID: 18241962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP).
    Alexander L; Birkhead G; Guerra F; Helms C; Hinman A; Katz S; LeBaron CW; Modlin J; Murphy TV; ;
    Arch Pediatr Adolesc Med; 2004 Dec; 158(12):1106-12. PubMed ID: 15583093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
    Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
    Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis.
    Swartz TA; Handsher R; Manor Y; Stoeckel P; Barkay A; Mendelson E; Leventhal A
    Vaccine; 1998 Dec; 16(20):2090-5. PubMed ID: 9796069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A ten-year experience in control of poliomyelitis through a combination of live and killed vaccines in two developing areas.
    Tulchinsky T; Abed Y; Shaheen S; Toubassi N; Sever Y; Schoenbaum M; Handsher R
    Am J Public Health; 1989 Dec; 79(12):1648-52. PubMed ID: 2817193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined OPV and IPV program in control of poliomyelitis in two endemic areas--a potential tool in the struggle to eradicate poliomyelitis.
    Tulchinsky TH
    Public Health Rev; 1993-1994; 21(1-2):153-6. PubMed ID: 8041883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness of inactivated poliomyelitis vaccine for primary vaccination].
    Li CG; Ying ZF; Wang JF; Fang HH; Li YP; Li RC; Bonnet MC; Zhang YP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Jun; 43(6):501-3. PubMed ID: 19950717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
    Chowdhary R; Dhole TN
    J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The perspective of global eradication of poliomyelitis].
    Knolle H; Egli A; Candrian U
    Gesundheitswesen; 2004 Jan; 66(1):1-6. PubMed ID: 14767784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case for developing antiviral drugs against polio.
    Collett MS; Neyts J; Modlin JF
    Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a program successfully combining live and killed polio vaccines.
    Lasch EE; Abed Y; Gerichter CB; Massri ME; Marcus O; Hensher R; Goldblum N
    Isr J Med Sci; 1983 Nov; 19(11):1021-3. PubMed ID: 6662685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.